Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch Announces New "AF TeleClinic"

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
New Products/LifeWatch AG
11.05.2010
First in Series of Treatment-Specific Remote Patient Monitoring 
Services
Chicago, IL / USA May 11 2010 - LifeWatch Services, Inc., a 
subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will unveil 
its advanced AF TeleClinic service offering this week at the Heart 
Rhythm Society (HRS) Annual Meeting taking place in Denver, Colorado.
The AF TeleClinic service, empowered with the latest communication, 
IT and medical technologies, ensures physicians are well equipped to 
deliver optimal diagnostic and treatment options to their patients. 
Featuring robust reporting options with key charting metrics, and a 
comprehensive suite of workflow and data management tools for 
monitoring Atrial Fibrillation patients, the AF TeleClinic aims to 
improve the standards of care and clinical outcomes. The timely and 
accurate reporting features of the AF TeleClinic can facilitate 
better treatment options that improve a patient's quality of life, 
and reduce unnecessary and costly hospital readmissions and emergency
room visits. Physicians further benefit from built-in processes 
designed to streamline their practice workflows and provide staffing 
efficiencies.
Atrial fibrillation, a disorder found in about 2.2 million Americans,
is a major cause of strokes in the U.S. Approximately 15 percent of 
strokes occur in people with atrial fibrillation, and the likelihood 
of developing this condition increases with age. Three to five 
percent of people over 65 have atrial fibrillation. LifeWatch first 
addressed this condition with its unique AF Patient Care monitoring 
program in 2008.
"In evaluating the best solution for monitoring of our patients being
treated for Atrial Fibrillation, we selected the LifeWatch AF patient
care program which provides efficient patient scheduling and enhanced
arrhythmia reporting options", stated Vivek Reddy, MD, FHRS, FACC 
Director, Cardiac Arrhythmia Service, The Leona M. and Harry B. 
Helmsley Charitable Trust Professor of Medicine in Cardiac 
Electrophysiology
Building on this highly successful program, LifeWatch designed the AF
TeleClinic with more advanced features and benefits that conform to 
the new standards of practice and care for AF post procedure follow 
up monitoring as recommended by the HRS consensus statement, 
including:
* AF Ablation
* Drug Titration Therapy
* Cardioversion
The timesaving and cost-effective features of the AF TeleClinic 
include automatic scheduling of patient follow up monitoring, 
powerful reporting formats providing additional important data, 
metrics and trending charts. For instance, an advanced "Afib" report 
generates test-to-test serial comparative metrics for validation of 
procedures, treatment success and efficacy. The seamless data 
management and workflow algorithms increase staffing efficiencies and
free up time for non-administrative patient care duties that are more
critical.
The AF TeleClinic "first in the industry" bundled telemedicine 
service, will be followed by a series of disease-specific monitoring 
TeleClinics that LifeWatch is developing. Each LifeWatch TeleClinic 
will provide a safe and effective care model outside of the costly in
hospital model. The integration of colliding technologies like remote
patient monitoring services, wireless communication platforms, 
wearable technologies and Electronic Medical Records (EMR) serves to 
proactively reduce LOS (Length of Stay) for patients in the hospital 
and prevent unnecessary readmissions due to minor follow up 
situations like compliance and false alarms. The use of advanced and 
agnostic technologies will enable LifeWatch to collaborate with any 
provider in the development of successful service models that ensure 
the safety and well-being of patients in a timely manner.
"The launch of our first TeleClinic service offering is an exciting 
opportunity which directly supports the emerging health care reform 
initiatives in the U.S. " declared Brent Cohen, CEO, LifeWatch AG. 
"As a pioneer in telemedicine, LifeWatch has a strong commitment to 
develop advanced and cutting edge technologies that improve patient 
outcomes, reduce the costs of care, and deliver valuable time 
management processes that physicians need".
About LifeWatch AG:
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on 
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare 
technology and solution company, specializing in advanced telehealth 
systems and wireless remote patient monitoring services. LifeWatch 
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the 
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent 
company of LifeWatch Services Inc., a leading US-based cardiac 
monitoring service provider, and manufacturer of telecardiology 
products. LifeWatch is also introducing a new program for Home 
SleepTesting of Obstructive Sleep Apnea (OSA) patients under the 
brand name NiteWatch. For additional information, please visit 
www.lifewatch.com and www.nitewatchservices.com.
Sign-up for customized E-mail alerts and documentation requests is 
available at http://production.investis.com/lifewatch/alert-service/
This press release includes forward-looking statements. All 
statements other than statements of historical facts contained in 
this press release, including statements regarding future results of 
operations and financial position, business strategy and plans and 
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify 
forward-looking statements. LifeWatch AG has based these 
forward-looking statements largely on current expectations and 
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business 
strategy, short term and long term business operations and 
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking 
events and circumstances described may not occur and actual results 
could differ materially and adversely from those anticipated or 
implied in the forward-looking statements. All forward-looking 
statements are based only on data available to LifeWatch AG at the 
time of the issue of this press release. LifeWatch AG does not 
undertake any obligation to update any forward-looking statements 
contained in this press release as a result of new information, 
future events or otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF 
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR 
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.  THIS 
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN 
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH 
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE 
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN 
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE 
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. 
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.  ANY 
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG 
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED 
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL 
STATEMENTS OF THE ISSUER.
end of announcement                               euro adhoc

Further inquiry note:

Woo Kim, Senior Vice President of Strategy and Business Development, LifeWatch
Tel +1 847 813 4299 | Fax +1 847 813 24 48 | Email wkim@lifewatch.com

Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG
  • 11.05.2010 – 06:50

    EANS-Adhoc: LifeWatch AG to announce departure of Reuven Freudinger

    ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/LifeWatch AG 11.05.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service ...

  • 11.05.2010 – 06:46

    EANS-Adhoc: LifeWatch reports on results for the First Quarter 2010

    ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report/LifeWatch AG Q1 2010 11.05.2010 • Ongoing positive cash flow • ACT patient enrollments up 37% to 21,099 patients • The first 300 patient enrollments for the NiteWatch service • Additions of managers with proven track record to LifeWatch ...